27 results on '"de Marinis, F."'
Search Results
2. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
3. Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making
4. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
5. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
6. Second-line chemotherapy for non-small cell lung cancer
7. Treatment of advanced non-small cell lung cancer
8. Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease
9. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy
10. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials
11. Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer
12. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
13. EFFECTIVENESS AND SAFETY OF AN INDUCTION THERAPY WITH EPOETIN ALPHA IN LUNG CANCER PATIENTS SUFFERING FROM MODERATE-SEVERE ANEMIA UNDERGOING CHEMOTHERAPY
14. RADIOCHEMOTHERAPY-ASSOCIATED ANEMIA AND SURVIVAL: AN ANALYSIS OF PUBLISHED STUDIES
15. OPTIMIZED SCHEDULE OF GEMCITABINE (G), PACLITAXEL (T) AND CISPLATIN (P) IN THE TREATMENT OF STAGE IIIB/IV NON- SMALL CELL LUNG CANCER (NSCLC): RESULTS OF A PHASE II STUDY
16. IMPACT OF THIRD-LINE ZD 1839 THERAPY ON PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD FAILED PRIOR PLATINUM AND/OR DOCETAXEL-BASED REGIMENS (ASTRA ZENECA EXPANDED ACCESS PROGRAMME)
17. Gemcitabine-oxaliplatin (GEMOX) chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase-II study: 2576
18. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
19. A THREE-WEEK SCHEDULE OF GEMCITABINE PLUS CISPLATIN AS INDUCTION CHEMOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MONOINSTITUTIONAL PHASE II STUDY
20. PHASE I/II TRIAL OF GEMCITABINE ADMINISTERED EVERY OTHER WEEK AND CISPLATIN IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): FEASIBILITY OF A NEW SCHEDULE
21. Quality of life in lung cancer patients
22. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial
23. INDUCTION THERAPY (IT) WITH PACLITAXEL (P) AND CBDCA (C) FOLLOWED BY HYPERFRACTIONATED RADIOTHERAPY (HFR) + WEEKLY CONCURRENT CHEMOTHERAPY (WT) AND SUBSEQUENT MANTEINANCE THERAPY IN UNRESECTABLE NSCLC (STAGE IIIA BULKY, STAGE IIIB).
24. GEMCITABINE AND CISPLATIN AS INDUCTION CHEMOTHERAPY IN STAGE IIIAN2/IIIB NON-SMALL CELL LUNG CANCER (NSCLC). A MONO-INSTITUTIONAL PHASE II STUDY WITH A 21 DAYS SCHEDULE.
25. CISPLATIN AND GEMCITABINE (GC) AS NEOADJUVANT THERAPY OF STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY
26. TOLERABILITY AND ACTIVITY OF WEEKLY PACLITAXEL AND CARBOPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
27. CISPLATIN (P), ETOPOSIDE (E) AND GEMCITABINE (G) IN UNTREATED PATIENTS WITH SMALL CELL LUNG CANCER (SCLC): RESULTS OF A MULTI-INSTITUTIONAL PHASE II TRIAL OF GOL (ONCOLOGICAL GROUP OF LAZIO).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.